ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2022
Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Multifunctional nanosponges in cancer therapy: Integrating targeted drug delivery and theranostic potential.International journal of pharmaceutics: X · 2025Review
- Mucoadhesive Carbohydrate-Based Polymeric Nanocapsule Loaded with Palbociclib for Enhanced GIT Retention and In Vitro Anticancer Efficacy in MDA-MB-231 Cells.AAPS PharmSciTech · 2025Article
- Effect of palliative radiotherapy and cyclin-dependent kinase 4/6 inhibitor on breast cancer cell lines.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Physicochemical Characterization, Drug Release, Stability, and Cytotoxicity of Cross-Linked Curdlan-Based Nanosponges for α-Amyrin and Higenamine Delivery.Turkish journal of pharmaceutical sciences · 2025Article
- A quality-by-design approach to develop abemaciclib solid lipid nanoparticles for targeting breast cancer cell lines.Therapeutic delivery · 2025Article
- Nanosponges-road Less Explored Changing Drug Delivery Approach: An Explicative Review.Current pharmaceutical biotechnology · 2025Review
- Novel indolyl 1,2,4-triazole derivatives as potential anti-proliferative agents:RSC medicinal chemistry · 2024Article
- Nanosponge: A promising and intriguing strategy in medical and pharmaceutical Science.Heliyon · 2024Review
- Ribociclib Hybrid Lipid-Polymer Nanoparticle Preparation and Characterization for Cancer Treatment.Polymers · 2023Article
- Targeted Fisetin-Encapsulated β-Cyclodextrin Nanosponges for Breast Cancer.Pharmaceutics · 2023Article
- Current advances in nanodrug delivery systems for malaria prevention and treatment.Discover nano · 2023Review
- Methanol extract of Iraqi Kurdistan RegionFrontiers in chemistry · 2023Article
- Preparation and Evaluation of Diosmin-Loaded Diphenylcarbonate-Cross-Linked Cyclodextrin Nanosponges for Breast Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Sustainable development through the bio-fabrication of ecofriendly ZnO nanoparticles and its approaches to toxicology and environmental protection.Biomass conversion and biorefinery · 2022Article
- Nanosponges for Drug Delivery and Cancer Therapy: Recent Advances.Nanomaterials (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abemaciclib (AC) is a novel, orally available drug molecule approved for the treatment of breast cancer. Due to its low bioavailability, its administration frequency is two to three times a day that can decrease patient compliance. Sustained release formulation are needed for prolong the action and to reduce the adverse effects. The aim of current study was to develop sustained release NSs of AC. Nanosponges (NSs) was prepared by emulsion-solvent diffusion method using ethyl-cellulose (EC) and Kolliphor P-188 (KP-188) as sustained-release polymer and surfactant, respectively. Effects of varying surfactant concentration and drug: polymer proportions on the particle size (PS), polydispersity index (PDI), zeta potential (ζP), entrapment efficiency (%EE), and drug loading (%DL) were investigated. The results of AC loaded NSs (ACN1-ACN5) exhibited PS (366.3-842.2 nm), PDI (0.448-0.853), ζP (-8.21 to -19.7 mV), %EE (48.45-79.36%) and %DL (7.69-19.17%), respectively. Moreover, ACN2 showed sustained release of Abemaciclib (77.12 ± 2.54%) in 24 h Higuchi matrix as best fit kinetics model. MTT assay signified ACN2 as potentials cytotoxic nanocarrier against MCF-7 and MDA-MB-231 human breast cancer cells. Further, ACN2 displayed drug release property without variation in the % release after exposing the product at 25 °C, 5 °C, and 45 °C storage conditions for six months. This investigation proved that the developed NSs would be an efficient carrier to sustain the release of AC in order to improve efficacy against breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.